MX355063B - Calcimiméticos y métodos para su uso. - Google Patents
Calcimiméticos y métodos para su uso.Info
- Publication number
- MX355063B MX355063B MX2014005662A MX2014005662A MX355063B MX 355063 B MX355063 B MX 355063B MX 2014005662 A MX2014005662 A MX 2014005662A MX 2014005662 A MX2014005662 A MX 2014005662A MX 355063 B MX355063 B MX 355063B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- calcimimetics
- effective
- levels
- kidney disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 239000000199 parathyroid hormone Substances 0.000 abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 abstract 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 abstract 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000002092 calcimimetic effect Effects 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558389P | 2011-11-10 | 2011-11-10 | |
| PCT/US2012/064717 WO2013071262A1 (en) | 2011-11-10 | 2012-11-12 | Calcimimetics and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005662A MX2014005662A (es) | 2014-11-10 |
| MX355063B true MX355063B (es) | 2018-04-04 |
Family
ID=47258113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005662A MX355063B (es) | 2011-11-10 | 2012-11-12 | Calcimiméticos y métodos para su uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140315809A1 (enExample) |
| EP (1) | EP2776129B2 (enExample) |
| JP (2) | JP6204369B2 (enExample) |
| CN (2) | CN109985228A (enExample) |
| AU (1) | AU2012335009B2 (enExample) |
| CA (1) | CA2854911C (enExample) |
| HK (1) | HK1202086A1 (enExample) |
| MX (1) | MX355063B (enExample) |
| WO (1) | WO2013071262A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4874954B2 (ja) | 2004-04-21 | 2012-02-15 | エノビア ファーマ インコーポレイティド | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 |
| CN107674114B (zh) | 2009-07-29 | 2022-10-25 | 凯伊药品公司 | 用于降低甲状旁腺激素水平的治疗剂 |
| PL3013318T3 (pl) | 2013-06-28 | 2018-03-30 | Amgen Inc. | Stabilny ciekły preparat związku amg 416 (welkalcetyd) |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| US20170304228A1 (en) * | 2014-10-24 | 2017-10-26 | Launx Biomedical Co., Ltd. | New indication of cinacalcet hcl pharmaceutical composition for treating cancer |
| ES3038086T3 (en) | 2014-12-05 | 2025-10-09 | Alexion Pharma Inc | Treating seizure with recombinant alkaline phosphatase |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| EP3250227A2 (en) * | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| KR20240158374A (ko) | 2017-03-31 | 2024-11-04 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| EP3867650A1 (en) * | 2018-10-18 | 2021-08-25 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| JP7796013B2 (ja) * | 2019-12-09 | 2026-01-08 | 北京拓界生物医薬科技有限公司 | カルシウム感知受容体アゴニスト化合物及びその使用 |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| US20230331779A1 (en) * | 2020-09-10 | 2023-10-19 | Shaanxi Micot Technology Co., Ltd. | Bispecific fusion polypeptide compound |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| US20240269227A1 (en) * | 2021-06-08 | 2024-08-15 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist composition and application thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| EP0917537B1 (en) * | 1996-07-31 | 2005-09-07 | The General Hospital Corporation | Novel parathyroid hormone-related peptide analogs |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| AU2001278956B2 (en) | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
| US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| BRPI0609524A2 (pt) * | 2005-03-17 | 2011-10-18 | Amgen Inc | uso de uma quantidade terapeuticamente eficaz de um composto calcimimético |
| JP5645408B2 (ja) | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| CA2701638A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
| CN107674114B (zh) * | 2009-07-29 | 2022-10-25 | 凯伊药品公司 | 用于降低甲状旁腺激素水平的治疗剂 |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2012
- 2012-11-12 CN CN201910103503.4A patent/CN109985228A/zh active Pending
- 2012-11-12 AU AU2012335009A patent/AU2012335009B2/en active Active
- 2012-11-12 JP JP2014541386A patent/JP6204369B2/ja active Active
- 2012-11-12 CA CA2854911A patent/CA2854911C/en active Active
- 2012-11-12 US US14/357,702 patent/US20140315809A1/en not_active Abandoned
- 2012-11-12 EP EP12791926.4A patent/EP2776129B2/en active Active
- 2012-11-12 HK HK15102648.5A patent/HK1202086A1/xx unknown
- 2012-11-12 CN CN201280066707.1A patent/CN104168955A/zh active Pending
- 2012-11-12 MX MX2014005662A patent/MX355063B/es active IP Right Grant
- 2012-11-12 WO PCT/US2012/064717 patent/WO2013071262A1/en not_active Ceased
-
2016
- 2016-03-01 US US15/057,742 patent/US20160175383A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/603,279 patent/US20170252397A1/en not_active Abandoned
- 2017-06-23 JP JP2017123032A patent/JP2017160269A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2854911C (en) | 2019-09-24 |
| CN109985228A (zh) | 2019-07-09 |
| AU2012335009A1 (en) | 2014-05-29 |
| MX2014005662A (es) | 2014-11-10 |
| US20160175383A1 (en) | 2016-06-23 |
| EP2776129A1 (en) | 2014-09-17 |
| HK1202086A1 (en) | 2015-09-18 |
| CA2854911A1 (en) | 2013-05-16 |
| EP2776129B1 (en) | 2017-03-29 |
| US20170252397A1 (en) | 2017-09-07 |
| EP2776129B2 (en) | 2020-06-17 |
| US20140315809A1 (en) | 2014-10-23 |
| WO2013071262A1 (en) | 2013-05-16 |
| AU2012335009B2 (en) | 2017-08-31 |
| JP2015502346A (ja) | 2015-01-22 |
| JP6204369B2 (ja) | 2017-09-27 |
| JP2017160269A (ja) | 2017-09-14 |
| CN104168955A (zh) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355063B (es) | Calcimiméticos y métodos para su uso. | |
| MX374205B (es) | Metodo para preparar amg 416. | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| MX2017006286A (es) | Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r. | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| EA201270803A1 (ru) | Тиоацетатные соединения, композиции на их основе и способы их применения | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| MX2014008189A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
| EA201792465A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| WO2014015157A3 (en) | Sigma receptor ligands for modulating cellular protein homeostasis | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| MX378726B (es) | Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares. | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| MX375476B (es) | Composición farmacéutica que comprende empagliflozina, métodos para tratamiento y sus usos. | |
| WO2009006548A3 (en) | Treatment for anxiety | |
| IN2014CN04014A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |